Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

MLA

Stephan Sachs, et al. “Correction: GIP Receptor Agonism Improves Dyslipidemia and Atherosclerosis Independently of Body Weight Loss in Preclinical Mouse Model for Cardio-Metabolic Disease.” Cardiovascular Diabetology, vol. 23, no. 1, Sept. 2024, pp. 1–2. EBSCOhost, https://doi.org/10.1186/s12933-024-02407-8.

APA

Stephan Sachs, Anna Götz, Brian Finan, Annette Feuchtinger, Richard D. DiMarchi, Yvonne Döring, Christian Weber, Matthias H. Tschöp, Timo D. Müller, & Susanna M. Hofmann. (2024). Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovascular Diabetology, 23(1), 1–2. https://doi.org/10.1186/s12933-024-02407-8

Chicago

Stephan Sachs, Anna Götz, Brian Finan, Annette Feuchtinger, Richard D. DiMarchi, Yvonne Döring, Christian Weber, Matthias H. Tschöp, Timo D. Müller, and Susanna M. Hofmann. 2024. “Correction: GIP Receptor Agonism Improves Dyslipidemia and Atherosclerosis Independently of Body Weight Loss in Preclinical Mouse Model for Cardio-Metabolic Disease.” Cardiovascular Diabetology 23 (1): 1–2. doi:10.1186/s12933-024-02407-8.